A Closing Thought

Articles

Undertaking an assessment of the POS can be coupled with the product profile and safety assessments of compounds prior to launching a clinical trial.

Predicting the Probability of Success in Clinical Drug Development

What small “nudges” can serve as reminders and relevant motivators to help patients meet their goals, talk to a physician, explore a clinical trial, or stick with a treatment?

Relying on Data and Behavior Science to Unlock Real Change

The “citizen data scientist” is the person with no official data scientist training who uses the latest tools and technologies to handle data wrangling duties, analyze data, and create reports and models.

Non-Data Scientists: The Evolving Role of Clinical Data Management

Patient advocacy organizations are swaying away from a traditional model of granting academic researchers to now supporting biotechnology and pharma companies.

The Rise of Shared Digital Health Economy and Promise of Accelerated Clinical Research

The availability of FHIR-based APIs enabling patients to access and use their healthcare data for multiple purposes has opened a door to an entirely new world of opportunities for partnering with patients on clinical studies.

Patients as Partners in the API Era

Pharma and diagnostics companies need to strengthen alignment in Alzheimer’s disease research-to help turn science and data into actionable medical innovations.

Closer Pharma-Diagnostic Collaboration is Key to Alzheimer’s Drug R&D

Key tips and resources to help evade the common traps of market landscaping-today an increasingly high-stakes and comprehensive task during clinical development.    

How to Avoid Common Pitfalls of Market Landscaping

To support complex in-home clinical research and investigative sites, well-designed trials must produce the same high-quality data as traditional sites. 

Ensuring High-Quality Data in Complex, In-Home Clinical Trials

With more common cancers now increasingly broken down by specific genomic defects, the future of research for any cancer is entirely, and unequivocally, molecular.

Any Cancer Can Be a 'Rare Cancer'

Lori Goldberg is CEO, Silverlight Digital

Digital media is becoming a crucial vehicle for finding “Patient X” for rare disease drug trials. Three areas in particular where digital media is helping with the detective work are explored.  